Clinical significance of cardiovascular dysmetabolic syndrome

Current Controlled Trials in Cardiovascular Medicine

Volumn 3, Issue , 2002, Pages

  Deedwania, Prakash C ^a,b,c  

^a VA Central California Health Care   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

Cardiovascular dysmetabolic syndrome; Coronary heart disease; Diabetes mellitus; Hyperinsulinemia; Insulin resistance

Indexed keywords

ACARBOSE; INSULIN; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE;

APPETITE DISORDER; ATHEROSCLEROSIS; BODY WEIGHT DISORDER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL FEATURE; CLINICAL TRIAL; DIABETES MELLITUS; DISABILITY; DISEASE ASSOCIATION; DRUG MECHANISM; DYSLIPIDEMIA; ENDOCRINE DISEASE; EPIDEMIC; GASTROINTESTINAL SYMPTOM; HEMODYNAMICS; HIGH RISK PATIENT; HUMAN; HUNGER; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; KINESIOTHERAPY; LACTIC ACIDOSIS; METABOLIC DISORDER; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; RISK ASSESSMENT; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; WEIGHT GAIN;

EID: 0038816761     PISSN: 14686694     EISSN: 14686694     Source Type: Journal    
DOI: 10.1186/1468-6708-3-2     Document Type: Review

References (24)

1. Deedwania PC: The deadly quartet revisited. Am J Med 1998, 105:1S-3S
2. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229-234
3. Zimmet PZ, Alberti KGMM: The changing face of macrovascular disease in non-insulin-dependent diabetes mellitus: an epidemic in progress. Lancet 1997, 350(suppl 1):1-4
4. Eastman RC, Keen H: The impact of cardiovascular disease on people with diabetes: the potential for prevention. Lancet 1997, 350(suppl 1):29-32
5. Klein R: Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 1995, 18:258-268
6. Nathan DM, Meigs J, Singer DE: The epidemiology of cardiovascular disease in type 2 diabetes mellitus: how sweet it is... or is it? Lancet 1997, 350(suppl 1):4-9
7. DeFronzo RA: Insulin resistance, hyperinsulinemia, and coronary artery disease: a complex metabolic web. J Cardiovasc Pharmacol 1992, 20(suppl 11):S1-S16
8. DesPres J-P, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, Lupien PJ: Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996, 334:952-957
9. Grossman E, Messerli FH: Diabetic and hypertensive heart disease. Ann intern Med 1996, 125:304-310
10. Solymoss BC, Marcil M, Chaour M, Gilfix BM, Poitras AM, Campeau L: Fasting hyperinsulinism, insulin resistance syndrome, and coronary artery disease in men and women. Am J Cardiol 1995, 76:1152-1156
11. Hseuh WA, Law RE: Cardiovascular risk continuum: implications of insulin resistance and diabetes. Am J Med 1998, 105(suppl 1A):4S-14S
12. Reaven GM: Role of insulin resistance in human disease. Diabetes 1988, 37:1595-1607
13. Fagan TC, Deedwania PC: The cardiovascular dysmetabolic syndrome. Am J Med 1998, 105(suppl 1A):77S-82S
14. Peters AL, Schriger DL: The new diagnostic criteria for diabetes: the impact on management of diabetes and macrovascular risk factors. Am J Med 1998, 105(suppl 1A):15S-19S
15. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Commission on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997, 20:1183-1197
16. Joubert PH, Venter HL, Foukardis GN: The effect of miglitol and acarbose after an oral glucose load: a novel hypoglycaemic mechanism? Br J Clin Pharmacol 1990, 30:391-396
17. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE: Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995, 333:550-554
18. Phillips PJ, Scicchitano R, Clarkson AR, Gilmore HR: Metformin associated lactic acidosis. Aust NZ J Med 1978, 8:281-284
19. Ciraldi TP, Huber-Knudsen K, Hickman M, Olefsky JM: Regulation of glucose transport In cultured muscle cells by novel hypoglycemic agents. Metabolism 1995, 44:976-982
20. Fijuwara T, Okuno A, Yoshioka S: Suppression of hepatic gluconeogenesis in long-term troglitaxone treated diabetic KK and C57BL/Ksj-db/db mice. Metabolism 1995, 44:486-490
21. Law RE, Meehan WP, Xi XP, Graf K, Wuthrich DA, Coats W, Faxon D, Hsueh WA: Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest 1996, 98:1897-1905
22. Ghazzi MN, Perez JE, Antonucci TK, Driscoll JH, Huang SM, Faja BW, The Troglitazone Study Group, Whitcomb RW: Cardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes 1997, 46:433-439
23. Henry RR: Thiazolidinediones. Endocrinol Met Clin North Am 1997, 26:553-573
24. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM: Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 1992, 15:193-203